Vra

occhio candelona con volumi alti in corso ;)
 
la odio ..........lho incarico da 2,25 piu perdita cambio cosi imparo a non stopparmi..non fate come me .....e' un titolo di m... auguro achei la prende di fare un 300%...tanto sognare non costa niente ma stoppatevi che questi sono titoli che sono destinati al fallimento
 
Un ciofegone cha va bene oggi

Viragen Antibody Enhances Effect of Leading Cancer Drug



In Vitro Study Shows Benefit of Anti-CD55 Antibody and Rituxan(R)
PLANTATION, Fla., March 17 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today reported that its anti-cancer product, the anti-CD55 antibody, was found to significantly enhance the activity of Rituxan(R) when both drugs were used together in a cell-based evaluation study. The anti-CD55 antibody is under an exclusive option from Cancer Research Technology (U.K.), and is being developed for the treatment of a broad range of solid tumors. These preliminary results indicate its potential in improving the efficacy of leading cancer therapies.

Previous laboratory studies confirmed that the anti-CD55 antibody binds to a specific target expressed on the surface of tumor cells and removes one of the tumor's most important protective mechanisms, thereby making cancer cells vulnerable to attack by the immune system or other anti-cancer products. In this in vitro study, the antibody was combined with Rituxan(R) (Rituximab), a leading cancer medication with global sales of more than $1.5 billion in 2004 that is jointly marketed by Biogen Idec, Inc. and Genentech, Inc.

The results showed that the combination of the anti-CD55 antibody and Rituxan(R) led to a significant increase in the destruction of cancer cells as compared to Rituxan(R) alone. The study was conducted by researchers at Viragen (Scotland) Ltd.

Karen Jervis, Ph.D., Viragen's Director of Product Development, explained, "There is much published data suggesting that the efficacy of many therapeutic products, including monoclonal antibodies, may be limited by the presence of certain proteins on tumor surfaces that protect the tumor from attack by the immune system. One of these proteins is CD55, which is expressed on most tumor cells at far higher levels than on normal cells, and its function helps prevent the destruction of tumor cells. We have developed a unique anti-CD55 antibody that effectively removes this protective effect.

"We have previously demonstrated that the anti-CD55 antibody binds to the CD55 protein on the tumor cell's surface with great specificity and deactivates its defense," she continued. "Our new results using the antibody in tandem with Rituxan(R) are very encouraging as they demonstrate the synergistic effect of 'anti-CD55' when combined with a proven antibody in vitro. We believe this same beneficial effect may also be realized when we use the antibody with other cancer products, and we hope to yield similar results with other commercial anti-cancer agents."

The development of the antibody has been funded in part by an $833,000 grant awarded to Viragen (Scotland) Ltd. from the Scottish Government (Scottish Executive) in April 2004, and Viragen scientists continue to design and conduct preclinical studies in support of this program.

Viragen undertook this study initiative on its own behalf to determine the potential effects of co-therapy with the anti-CD55 antibody. Viragen has no agreements with Biogen Idec, Inc. or Genentech, Inc., and did not collaborate with either company in connection with the study. The anti-CD55 antibody is not approved for sale in any market or territory, and human clinical trials will be required prior to seeking approval from any international regulatory agency.

Anti-CD55 Antibody Project:

The University of Nottingham (England) and Viragen are developing the anti-CD55 antibody to block the protective effect of the protein CD55 on the surface of tumor cells. The protein CD55 is one of a number of proteins that protect normal healthy cells from being destroyed by the complement system, part of the human immune response against disease. The problem arises when cancer cells also express this control protein at high levels to camouflage and protect the cancerous cells from the immune system.

The anti-CD55 antibody acts to remove the tumor's protective mechanism and is expected to boost patient response rates either as a stand-alone therapy or in combination with other antibodies. Viragen holds an option from Cancer Research Technology Limited to acquire an exclusive worldwide license to this technology with potential application in a number of cancer types.
 
Appena rientrato e mi trovo nel portafoglio una bella sorpresa,i vecchi amori prima o poi se li hai trattati bene ritornano................speriamo solo che non sia un fuoco di paglia..........il periodo e lo stesso del 2003 quando ha fatto un bel balzo avanti....vaiiiiiiiii...
 
Secondo me e' da tenere sotto il mirino.........mi ispira fiducia.....cosa dite esperti del forum?
 
Un'altro fuoco di paglia........bo....se fossi indovino a quest'ora potrei aiutare tutti i poveri del mondo......vediamo un po' cosa combinano con questo multiferone....tocchiamoci le p...e OK! :)
 
Piano piano......va su.... pero' domani in apertura ne mollo un po'.......mi ha fatto soffrire troppo........tengo quelle che valgono una scommessa.... OK!
 
Attenzione...attenzione...hanno ottenuto un'estensione delle quotazioni nell'amex fino a marzo 2007........io incomincio a seguirla per l'ennesima volta......
 
Con piacere vedo che finisco la settimana in verde.............+60%... OK! OK!
 
oK BASTA OTTENUTO UN +52%..............ALLA PROSSIMA...
 
c'è ancora qualquno dentro!che dite della news di ieri non ho capito commenti grazie
 
siete già tutti a sciare ... con i gain fatti buone feste
 
per caso ce ancora qualcuno su questa ciofechina??
 
VIRAGEN INC (AMEX:VRA) Delayed quote data

Last Trade: 0.40
Trade Time: 2:32PM ET
Change: 0.09 (29.03%)
Prev Close: 0.31
Open: 0.32
Bid: N/A
Ask: N/A
1y Target Est: N/A

Day's Range: 0.30 - 0.50
52wk Range: 0.25 - 0.80
Volume: 1,565,700
Avg Vol (3m): 224,076
Market Cap: 19.09M
P/E (ttm): N/A
EPS (ttm): -0.46
Div & Yield: N/A (N/A
 
Indietro